Nimesulide (NIMS), Uses, Side Effect, Dose

Nims
Sharing is Caring !!

Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.

Uses

  • Acute Pain
  • Dysmenorrhea
  • Osteoarthritic Pain

Mechanism of Action

The therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine.

Side Effect

Due to concerns about the risk of liver toxicity, nimesulide has been withdrawn from market in several countries (Spain, Finland, Belgium, Ireland, and United States). Liver problems have resulted in both deaths and the need for transplantation. This may occur in as little as three days after starting the medication.

Continuous use of nimesulide (more than 15 days) may cause the following side effects:

  • Diarrhea
  • Vomiting
  • Skin rash
  • Itchiness
  • Dizziness
  • Bitterness in mouth
  • Nausea
  • Heart burn
  • Epigastric pain
  • Pruritis
  • Somnolence

Special Precautions while taking Nimesulide.

  • Renal impairment
  • Heart failure
  • Alcohol abuse
  • Colitis
  • Crohns disease
  • Diverticulitis
  • Gastric ulcer
  • Diabetis mellitus
  • Hemarrhoids
  • Hepatic failure
  • Rectal irritation or bleeding

Dose

The usual Adult dose of Nimesulide 100mg BD.

If Dose Missed

Take the missed dose as soon as you remember. If it is almost the time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Interaction with Medicine

Methotrexate, Warfarin, Corticosteroids, Furosemide, Lithium

Realted Articles –

Sharing is Caring !!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA Approves First Targeted Therapy to Treat Aggressive Form of…
Cresta Posts Box by CP
error:
X